TLR4 and breast carcinoma: In breast cancer cells (MDA-MB-231 positive for TLR4), the presence of hyperoside increased apoptosis, decreased cell viability, and activated caspase-3, all of which made cancer cells more susceptible to the chemotherapy drug paclitaxel.